|
US5164410A
(en)
|
1988-01-09 |
1992-11-17 |
Takeda Chemical Industries, Ltd. |
Fumagillol derivatives and pharmaceutical compositions thereof
|
|
PH26256A
(en)
|
1988-08-12 |
1992-04-01 |
Fujisawa Pharmaceutical Co |
Oxaspiro [2,5] octane derivative
|
|
EP0359036B1
(en)
|
1988-09-01 |
1997-03-26 |
Takeda Chemical Industries, Ltd. |
Fumagillol derivatives
|
|
US5166172A
(en)
|
1988-09-01 |
1992-11-24 |
Takeda Chemical Industries, Ltd. |
Fumagillol derivatives and pharmaceutical compositions thereof
|
|
US5180738A
(en)
|
1988-09-01 |
1993-01-19 |
Takeda Chemical Industries |
Fumagillol derivatives and pharmaceutical compositions thereof
|
|
US5288722A
(en)
|
1989-03-06 |
1994-02-22 |
Takeda Chemical Industries, Ltd. |
6-amino-6-desoxyfumagillols, production and use thereof
|
|
DE69001187T2
(de)
|
1989-03-06 |
1993-07-08 |
Takeda Chemical Industries Ltd |
6-epifumagillole, ihre herstellung und ihre verwendung.
|
|
US6017954A
(en)
|
1989-08-10 |
2000-01-25 |
Children's Medical Center Corp. |
Method of treating tumors using O-substituted fumagillol derivatives
|
|
US5290807A
(en)
|
1989-08-10 |
1994-03-01 |
Children's Medical Center Corporation |
Method for regressing angiogenesis using o-substituted fumagillol derivatives
|
|
EP0415294A3
(en)
|
1989-08-31 |
1991-06-12 |
Takeda Chemical Industries, Ltd. |
Cyclohexanol derivatives, production and use thereof
|
|
TW282399B
(enExample)
|
1990-05-25 |
1996-08-01 |
Takeda Pharm Industry Co Ltd |
|
|
ATE205092T1
(de)
|
1992-01-30 |
2001-09-15 |
Takeda Chemical Industries Ltd |
Verfahren zur herstellung hoch-wasserlöslicher zyklodextrinkomplexe
|
|
ATE153854T1
(de)
|
1992-12-16 |
1997-06-15 |
Takeda Chemical Industries Ltd |
Stabile pharmazeutische zubereitung mit fumagillolderivaten
|
|
NZ304906A
(en)
|
1995-03-27 |
1999-06-29 |
Sanofi Sa |
Use of fumagillol or a fumagillol ester and an optionally saturated alkylcarboxylic or alkyldicarboxylic acid to fight intestinal infections
|
|
WO1997013509A1
(en)
|
1995-10-11 |
1997-04-17 |
Fujisawa Pharmaceutical Co., Ltd. |
Vascular permeation inhibitor
|
|
EP0799616A1
(en)
|
1996-04-01 |
1997-10-08 |
Takeda Chemical Industries, Ltd. |
Oral composition comprising a fumagillol derivative
|
|
WO1998005293A2
(en)
|
1996-08-02 |
1998-02-12 |
The Children's Medical Center Corporation |
Method of regulating the female reproductive system through angiogenesis inhibitors
|
|
WO1998056372A1
(en)
|
1997-06-09 |
1998-12-17 |
Massachusetts Institute Of Technology |
TYPE 2 METHIONINE AMINOPEPTIDASE (MetAP2) INHIBITORS AND USES THEROF
|
|
DE69824750T2
(de)
|
1997-10-31 |
2005-07-07 |
Children's Medical Center Corp., Boston |
Methoden zur regulierung der grösse und des wachstums von durchblutetem normalem gewebe
|
|
KR100357542B1
(ko)
|
1998-05-15 |
2002-10-18 |
주식회사종근당 |
푸마질롤 유도체 및 그 제조방법
|
|
KR100357541B1
(ko)
|
1998-05-15 |
2002-10-18 |
주식회사종근당 |
5-데메톡시 푸마질롤 유도체 및 그 제조방법
|
|
JP2000116337A
(ja)
|
1998-10-09 |
2000-04-25 |
Nippon Shokuhin Kako Co Ltd |
ペットフード
|
|
US6383471B1
(en)
|
1999-04-06 |
2002-05-07 |
Lipocine, Inc. |
Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
|
|
NZ515087A
(en)
|
1999-04-28 |
2003-11-28 |
Aventis Pharma Gmbh |
Tri-aryl acid derivatives as PPAR receptor ligands
|
|
JP2003530438A
(ja)
|
2000-04-12 |
2003-10-14 |
スミスクライン・ビーチャム・コーポレイション |
化合物および方法
|
|
US6323228B1
(en)
|
2000-09-15 |
2001-11-27 |
Abbott Laboratories |
3-substituted indole angiogenesis inhibitors
|
|
US6548477B1
(en)
|
2000-11-01 |
2003-04-15 |
Praecis Pharmaceuticals Inc. |
Therapeutic agents and methods of use thereof for the modulation of angiogenesis
|
|
EP1330447A2
(en)
|
2000-11-01 |
2003-07-30 |
Praecis Pharmaceuticals Incorporated |
Peptides as met-ap2 inhibitors
|
|
WO2002078699A1
(en)
|
2001-03-29 |
2002-10-10 |
Smithkline Beecham Corporation |
Compounds and methods
|
|
ATE440094T1
(de)
|
2001-09-27 |
2009-09-15 |
Equispharm Co Ltd |
Fumagillolderivate und verfahren zu deren herstellung
|
|
US6803382B2
(en)
|
2001-11-09 |
2004-10-12 |
Galderma Research & Development, S.N.C. |
Angiogenesis inhibitors and pharmaceutical and cosmetic use thereof
|
|
KR100451485B1
(ko)
|
2002-03-28 |
2004-10-06 |
주식회사종근당 |
푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물
|
|
US6989392B2
(en)
|
2002-06-18 |
2006-01-24 |
Abbott Laboratories |
2-Aminoquinolines as melanin concentrating hormone receptor antagonists
|
|
US20040067266A1
(en)
|
2002-10-07 |
2004-04-08 |
Toppo Frank R. |
Weight loss compound
|
|
US20040157836A1
(en)
|
2002-10-08 |
2004-08-12 |
Comess Kenneth M. |
Sulfonamides having antiangiogenic and anticancer activity
|
|
WO2004078113A2
(en)
|
2003-03-04 |
2004-09-16 |
Pharmacia Corporation |
Treatment and prevention of obesity with cox-2 inhibitors alone or in combination with weight-loss agents
|
|
KR20060130077A
(ko)
|
2003-12-29 |
2006-12-18 |
프래시스 파마슈티컬즈 인코포레이티드 |
메티오닌 아미노펩티다제-2 의 저해제 및 이의 용도
|
|
KR100552043B1
(ko)
*
|
2004-02-28 |
2006-02-20 |
주식회사종근당 |
푸마질롤 유도체를 포함하는 비만치료용 조성물
|
|
WO2006004803A1
(en)
|
2004-06-30 |
2006-01-12 |
Combinatorx, Incorporated |
Methods and reagents for the treatment of metabolic disorders
|
|
US20060045865A1
(en)
|
2004-08-27 |
2006-03-02 |
Spherics, Inc. |
Controlled regional oral delivery
|
|
US20100056623A1
(en)
|
2005-01-26 |
2010-03-04 |
Chong Kun Dang Pharmaceutical Corp. |
Fumagillol derivatives or method for preparation of fumagillol derivatives, and pharmaceutical compositions comprising the same
|
|
FR2886855B1
(fr)
|
2005-06-08 |
2009-07-17 |
Agronomique Inst Nat Rech |
Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocyliques
|
|
WO2006138475A2
(en)
|
2005-06-16 |
2006-12-28 |
Jenrin Discovery |
Mao-b inhibitors useful for treating obesity
|
|
JP2010531896A
(ja)
|
2007-06-26 |
2010-09-30 |
チルドレンズ メディカル センター コーポレーション |
治療的投与のためのＭｅｔＡＰ−２阻害剤ポリマーソーム
|
|
BRPI0820229A2
(pt)
|
2007-11-28 |
2017-05-09 |
A Stevenson Cheri |
conjugados de análogos de fumagilina biodegradáveis biocompatíveis
|
|
EP2317845A4
(en)
|
2008-07-18 |
2011-11-09 |
Zafgen Inc |
METHOD FOR TREATING AN OVERWEIGHT OR FATABLE PERSON
|
|
CN102239149B
(zh)
|
2008-10-06 |
2015-05-13 |
约翰·霍普金斯大学 |
喹啉化合物作为血管新生、人类甲硫氨酰氨肽酶、以及sirt1的抑制剂,以及治疗病症的方法
|
|
CA2741683C
(en)
|
2008-10-24 |
2016-03-22 |
Wake Forest University |
Platinum acridine anti-cancer compounds and methods thereof
|
|
WO2010065881A2
(en)
|
2008-12-04 |
2010-06-10 |
Zafgen Corporation |
Methods of treating an overweight or obese subject
|
|
US20120010290A1
(en)
|
2008-12-04 |
2012-01-12 |
Vath James E |
Methods of Treating an Overweight or Obese Subject
|
|
US20120004162A1
(en)
|
2008-12-04 |
2012-01-05 |
Vath James E |
Methods of Treating an Overweight or Obese Subject
|
|
US8642650B2
(en)
*
|
2008-12-04 |
2014-02-04 |
Zafgen, Inc. |
Methods of treating an overweight or obese subject
|
|
WO2011044506A2
(en)
|
2009-10-09 |
2011-04-14 |
Zafgen Corporation |
Sulphone compounds and methods of making and using same
|
|
BR112012016793A2
(pt)
*
|
2010-01-08 |
2018-07-31 |
Zafgen Corp |
compostos tipo fumagilol e métodos de fazer e usar os mesmos
|
|
WO2011085198A1
(en)
|
2010-01-08 |
2011-07-14 |
Zafgen Corporation |
Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph)
|
|
US20130023513A1
(en)
|
2010-01-12 |
2013-01-24 |
Hughes Thomas E |
Methods and Compositions for Treating Cardiovascular Disorders
|
|
WO2011127304A2
(en)
|
2010-04-07 |
2011-10-13 |
Zafgen Corporation |
Methods of treating an overweight subject
|
|
US20130210821A1
(en)
|
2010-05-27 |
2013-08-15 |
James E. Vath |
Methods for Treating Obesity
|
|
BR112013001613A2
(pt)
|
2010-07-22 |
2016-05-24 |
Zafgen Inc |
compostos tricíclicos e métodos para fazer e usar os mesmos.
|
|
MX339201B
(es)
|
2010-10-12 |
2016-05-13 |
Zafgen Inc |
Compuestos de sulfonamida y métodos para elaborarlos y usarlos.
|
|
PH12013500934A1
(en)
|
2010-11-09 |
2022-10-24 |
Zafgen Inc |
Crystalline solids of a metap-2 inhibitor and methods of making and using same
|
|
WO2012064928A1
(en)
|
2010-11-10 |
2012-05-18 |
Zafgen Corporation |
Methods and compositions for treating thyroid hormone related disorders
|
|
US20140011870A1
(en)
|
2010-11-29 |
2014-01-09 |
Zafgen, Inc. |
Methods of Treating Obesity Using an Effective Dose of a METAP-2 Inhibitor
|
|
JP2013543899A
(ja)
*
|
2010-11-29 |
2013-12-09 |
ザフゲン，インコーポレイテッド |
６−ｏ−（４−ジメチルアミノエトキシ）シンナモイルフマギロールの非連日投与を用いた肥満の治療
|
|
US20130316994A1
(en)
|
2010-11-29 |
2013-11-28 |
Zafgen, Inc. |
Methods of Reducing Risk of Hepatobiliary Dysfunction During Rapid Weight Loss with METAP-2 Inhibitors
|
|
US9321740B2
(en)
|
2011-01-26 |
2016-04-26 |
Zafgen, Inc. |
Tetrazole compounds and methods of making and using same
|
|
AU2012253759B2
(en)
|
2011-05-06 |
2016-01-21 |
Zafgen Inc. |
Tricyclic sulfonamide compounds and methods of making and using same
|
|
WO2012154679A1
(en)
|
2011-05-06 |
2012-11-15 |
Zafgen Corporation |
Tricyclic pyrazole sulfonamide compounds and methods of making and using same
|
|
US9290472B2
(en)
|
2011-05-06 |
2016-03-22 |
Zafgen, Inc. |
Partially saturated tricyclic compounds and methods of making and using same
|
|
WO2013033430A1
(en)
|
2011-09-02 |
2013-03-07 |
Wake Forest School Of Medicine |
Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof
|